Publications – Magnus Lindskog's group

Publications in DiVA (Lindskog)

Publications in DiVA (Sandelin)
 

Selected publications:

  1. Lindskog M, Wahlgren T, Sandin R, Kowalski J, Jakobsson M, Lundstam S, Ljungberg B, Harmenberg U. Overall survival (OS) in Swedish RCC patients treated 2000–2012: Update of the RENCOMP study. J Clin Oncol 33, 2015; suppl 7; 413.
     
  2. George J, Lim JS, Jang SJ, Cun Y, Ozretić LKong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, et al.. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015 Aug 6;524(7563):47-53.
     
  3. Sandelin M, Berglund A, Sundström M, Micke P, Ekman S, Bergqvist M, Bergström S, Koyi H, Brandén E, Janson C, Botling J. Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome. Anticancer Res. 2015 Jul;35(7):3979-85.
     
  4. Lindskog M, Tavelin B, Lundström S. Old age as risk indicator for poor end-of-life care quality - a population-based study of cancer deaths from the Swedish Register of Palliative Care. Eur J Cancer. 2015 Jul;51(10):1331-9.
     
  5. Stenman M, Laurell A, Lindskog M. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol. 2014 Mar;31(3):841.
     
  6. Sörenson S, Fohlin H, Lindgren A, Lindskog M, Bergman B, Sederholm C, Ek L, Lamberg K, Clinchy B. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. Eur J Cancer. 2013 Jan;49(1):115-20.
     
  7. Holgersson G, Sandelin M, Hoye E, Bergström S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Holgersson M, Lundström KL, Janson C, Birath E, Mörth C, Blystad T, Ewers SB, Löden B, Bergqvist M. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol. 2012 Dec;29(5):3176-82.
     
  8. Holgersson G, Sandelin M, Hoye E, Bergström S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Brodin O, Holgersson M, Lundström KL, Janson C, Ekberg L, Mörth C, Blystad T, Ewers SB, Löden B, Bergqvist M. The value of induction chemotherapy for survival in patients with non-small cell lung cancer treated with radiotherapy. Anticancer Res. 2012 Apr;32(4):1339-46.
     
  9. Cederblad L, Johansson S, Enblad G, Engström M, Blomquist E. Cancer of the parotid gland; long-term follow-up. A single centre experience on recurrence and survival. Acta Oncol. 2009;48(4):549-55.
     
  10. Sun A, Sörensen J, Karlsson M, Turesson I, Langström B, Nilsson P, Cederblad L, Bertling J, Riklund K, Johansson S. 1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging. 2007 May;34(5):651-7.